(lp0
S'Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November Motley Fool - Dec 6, 2016 Shares of Progenics Pharmaceuticals, Inc. , a small biotech with an oncology focus, rocketed up 76.5% in November, according to data from S&amp;P Global Market Intelligence.'
p1
aS"Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences GlobeNewswire  - Feb 8, 2017 NEW YORK, Feb. 08, 2017  -- Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that Mark Baker, Chief&nbsp;...Noticeable Analyst's Ideas: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ... - TRA"
p2
aS"Why Progenics Pharmaceuticals, Inc. Is Rising Today Motley Fool - Oct 4, 2016 It certainly is an exciting time to be an investor in Progenics. The company and its partner Valeant Pharmaceuticals  just launched an oral version of their opioid-induced constipation  drug Relistor in the third quarter. While the drug ...Brean Capital Assumes Buy on Progenics Pharmaceuticals, Inc. ; Sees 50 ... - Smarter AnalystProgenics Pharma : Profitability Could Come In '17 - Needham - StreetInsider.com"
p3
aS'Option Market Alert: Progenics Pharmaceuticals Inc Implied Price Swing Hits An ... CML News - Mar 19, 2017 Risk Alert: Before we dive into any analysis we simply note that Progenics Pharmaceuticals Inc  risk is elevated.'
p4
aS"Progenics Pharmaceuticals: 25% Upside Left After 60% Move? Seeking Alpha - Nov 20, 2016 My yearlong patience with Progenics Pharmaceuticals  finally seems to be finally paying off in spades. The stock has moved up some 60% so far in the month of November as investors finally appear to be recognizing the company's value and&nbsp;..."
p5
aS'Stock Volatility Risk Alert: Progenics Pharmaceuticals Inc Price Volatility ... CML News - 11 hours ago Before we cover the full analysis we make a quick alert here that Progenics Pharmaceuticals Inc  has seen its stock price whip around at an elevated level.'
p6
aS'An Inside Look at Trading Hot Stocks: Progenics Pharmaceuticals, Inc. (PGNX ... Post Analyst - 17 hours ago Progenics Pharmaceuticals, Inc. has a consensus buy rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 15.95% of shares outstanding.Company Stock Price of Progenics Pharmaceuticals Inc.  Decreases -3.05% - Times Money'
p7
aS'Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial ... GlobeNewswire  - Feb 23, 2017 NEW YORK, Feb. 23, 2017  -- Progenics Pharmaceuticals, Inc., , an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference&nbsp;...An End-of-Day Technical Review: Progenics Pharmaceuticals, Inc. (PGNX ... - Post AnalystStock Price of Progenics Pharmaceuticals Inc.  Increases 11.56% - Energy Index'
p8
aS'Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 ... Yahoo Finance - Mar 9, 2017 NEW YORK, March 09, 2017  -- Progenics Pharmaceuticals, Inc.  today announced financial results and provided a business update for the fourth quarter and full-year 2016.'
p9
aS'With An ROE OF 10.4% In The Past Year, Can Progenics Pharmaceuticals Inc (PGNX ... Simply Wall St - Mar 6, 2017 Progenics Pharmaceuticals Inc  delivered 10.4% ROE over the past year, compared to 27.38% generated by its industry.Investors Reviewing Stock: Progenics Pharmaceuticals Inc.  - Is storiesRating Change on Progenics Pharmaceuticals Inc.  - Energy Index'
p10
a.